Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's DiseaseStephen Salloway, H. Robert Brashear, Anton P. Porsteinsson et al.|New England Journal of Medicine|2014Cited by 2k
Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease DementiaRebecca E. Amariglio, Reisa A. Sperling, Michael Donohue et al.|JAMA Neurology|2015Cited by 206
Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: a selective reviewDorene M. Rentz, Steven H. Ferris, Mario A. Parra et al.|Alzheimer s Research & Therapy|2013Cited by 206
Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trialsEnchi Liu, Arthur Spirling, Mark E. Schmidt et al.|Neurology|2015Cited by 152